Tiziana Life Sciences has completed dosing the last patient in its Phase 2 trial of intranasal foralumab for early or mild Alzheimer's disease. The randomized, placebo-controlled study is testing the safety, tolerability, and potential efficacy of foralumab alone and combined with FDA-approved anti-amyloid drugs lecanemab or donanemab. The trial focuses on reducing neuroinflammation and improving cognitive function, with topline results expected in the first quarter of 2027. This study could establish immunomodulation as a new approach alongside existing Alzheimer's treatments.
Tiziana's Phase 2 Alzheimer's trial progress is noted here with Pluang's health sector data as context. For readers following health stocks, 93 of 150 US-listed health-sector stocks on Pluang rose today while 46 fell, as of Oct 16, 2026 19:01 WIB. Amneal Pharmaceuticals Inc. (AMRX) gained 1.30% to USD 19.50 with a typical hold time of 7 days, contrasting with Canopy Growth Corp (CGC) and Tilray Brands Inc (TLRY), which both rose about 1.25% but saw predominantly sell order activity and longer hold times of 39 and 31 days respectively.
Whole Lotta Dank, a Canadian cannabis brand platform, has launched its first brand, Dank Pack, debuting with Blueberry BBL available across Alberta. The company is expanding its portfolio with over 20 SKUs under regulatory review and is actively seek...
Nasdaq announced that trading in CN Healthy Food Tech Group Corp.'s common stock and warrants will resume on October 19, 2026, after being halted since October 1, 2025. The resumption marks the end of a year-long trading suspension, allowing investor...
David Solomon, CEO of Goldman Sachs, has been appointed as the new chair of The Business Council, taking over from Brian Cornell, Executive Chair of Target Corporation. This leadership change comes at a critical time as the Council addresses challeng...
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, expanding at a CAGR of 6.15%. Growth is fueled by advances in biologics, AI-driven drug discovery, specialty drugs, and manufacturing i...
SEDA Experts LLC has appointed Noor Ul Islam as Managing Director, enhancing its capabilities in risk management and securities practices. With nearly 30 years of experience at major financial institutions like Citibank and Barclays, Islam brings dee...
